When scientists advising President Obama came to analyze the U.S. response to the outbreak of H1N1, they identified several major bottlenecks that needed clearing. Poor yields from seed viruses were near the top of the list, and the scientists set a two year target for improving.
Titan's Probuphine could help FDA in its efforts to fight opioid abuse
The FDA is wrestling with a host of issues surrounding the highly addictive and often abused opioids and just recommended a drug that may provide some help in its effort.
Whooping cough is a tough disease to vaccinate against. Children are given five shots before they are old enough to go to school, yet even this multistep regime is failing to protect everyone. Last year a preteen booster shot was added to the vaccination plan in response to rising incidence.
Deep federal spending cuts triggered by sequestration are set to rock vaccine development and administration in the U.S. and beyond. The White House warns that the cuts will limit the number of vaccines federal agencies buy from GlaxoSmithKline ($GSK), Merck ($MRK), Sanofi ($SNY) and other manufacturers.
Computer technology is being used more widely in upping vaccination rates worldwide. A team of researchers, epidemiologists and software developers at Boston Children's Hospital rolled out a free online service that helps people locate nearby vaccine providers in an effort to boost immunization numbers.
Analysts expect the U.S. vaccine market to rack up to $12.8 billion in sales for 2012. And Transparency Market Research says the industry can expect to see 5.3% growth through 2018. But low vaccination rates among U.S. adults may hamper that upward trend.
The U.S. Centers for Disease Control confirmed this flu season has officially reached the level of an epidemic in the United States.
A fast, early and widespread flu season has gripped the United States, though deaths and hospitalizations are still below pandemic thresholds.
A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection.
Outbreak probe broadens as first patient sues compounding pharmacy
As a Minnesota woman became the first patient to sue New England Compounding over the meningitis outbreak suspected to have originated there, the company hired a prominent criminal-defense firm, and federal and state authorities stepped up their probes.